22nd Sep 2020 19:34
Vectura Group PLC - London-based drug delivery products firm - Notes announcement from partner Hikma Pharmaceuticals PLC "minor" complete response letter by the US Food & Drug Administration, relating to a new drug application for its generic version of the Advair Diskus inhaler. "Both Hikma and Vectura are committed to bringing this important product to the US market and remain confident in the submission," Vectura said.
Current stock price: 114.80 pence
Year-to-date change: up 24%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.LHikma Pharmaceuticals